BCRX•benzinga•
JP Morgan Maintains Overweight on BioCryst Pharma, Raises Price Target to $13
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga